Intercept Pharmaceuticals (ICPT) said Tuesday that an experimental medicine to treat the fatty liver disease known as NASH achieved its primary goal in a Phase 3 clinical trial, giving it a shot at becoming the first drug to treat the condition and turning it into a potential blockbuster commercial opportunity.
Based on the data collected from the clinical trial, Intercept said it would file marketing applications for the treatment in the U.S. and Europe in the second half of the year. The drug is called obeticholic acid, or OCA.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author
This is a really good news!! I hope this gets approved and successful, so that liver transplant can be avoided. Fatty liver diseases is at a rise in the US more and the main reason behind is binge drinking as alcohol is the driving force behind cirrhosis.
Source- https://www.myhealthyclick.com/alcoholic-fatty-liver-disease-on-rise-in-the-us-finds-study
Intercept stock was up more than 25% in the pre-market session after this positive data. But when the market opened that momentum was missing. https://news.alphastreet.com/intercept-pharmaceuticals-icpt-stock-surges-52-week-high-positive-data-from-liver-fibrosis-due-to-nash-drug-study/